Multiple factors impact the treatment of acute bacterial skin and skin structure infections (ABSSSI). BAXDELA is your path forward.
aBAXDELA clinical trials included a distribution of patients with obesity, hypertension, diabetes, and renal impairment (eGFR > 15 mL/min/1.73 m2).
Diabetes, age, obesity—multiple factors impact ABSSSI treatment.See Baxdela Results
Straightforward dosing in IV, oral, or IV to oral.See Baxdela Options
Microbiological activity against susceptible gram-negative and gram-positive pathogens, including MRSA.See Response Rates
For hospital or home, streamline access with MelintAssist.Explore Baxdela Options
Melinta Therapeutics, Inc. - The Antibiotics Company
For additional information about BAXDELA, call Melinta Therapeutics at 1-844-MED-MLNT (1-844-633-6568) or contact the US Food and Drug Administration at 1-888-INFO-FDA (1-888-463-6332).